By Michele Maatouk
Date: Monday 23 Aug 2021
LONDON (ShareCast) - (Sharecast News) - Abingdon Health surged on Monday after launching a Covid-19 antibody self-test it manufactured with BioSure.
The new test, for which BioSure is the legal manufacturer, has been CE marked specifically for self-testing. It uses a fraction of a drop of finger-prick blood and gives results in 20 minutes.
This allows individuals to know and monitor their own antibody status pre-vaccination, post vaccination and following infection with the SARS-CoV-2 virus. Abingdon said it will be particularly useful as populations worldwide continue to be vaccinated to monitor the effectiveness of an individual's immunity status.
Chief executive officer Chris Yates said: "We are delighted that BioSure have launched their product and equally happy to be their manufacturing partner. For individuals to be able to monitor their own antibody status at home is a great step in the management of Covid-19.
"Our own AbC-19 assay will complement this product and we expect the AbC-19 to gain additional utility in semi-quantitative format as recently announced. BioSure also distributes our AbC-19 test which is CE marked for professional use."
At 1400 BST, Abingdon shares were up 58% at 46p.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 7.75p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 12.10 |
52 Week Low | 6.75 |
Volume | 98,149 |
Shares Issued | 193.63m |
Market Cap | £15.01m |
Beta | 0.43 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
11:51 | 10,000 @ 7.74p |
11:00 | 17,500 @ 7.51p |
10:38 | 5,815 @ 7.75p |
10:21 | 6,795 @ 7.51p |
08:53 | 25,680 @ 7.77p |
You are here: research